Ing. Helmut Schütz
directly to content (skip navigation)
- Recent Threads in the Forum
- Spelling out FDA's pop BE model
- 2019 events listing
- Phoenix Connect
- Sampling time
- FDA: ANDA Submissions—Amendments to ANDAs Under GDFUA
- Repeat based on ISR data investigation
- Dose-proportionality versus dose-linearity
- BE criteria
- Bioanalysis discontinued subject
- Cmax is out of the range
- Outlier Tests
- Overall and Subpopulation p value consideration
- The results of sample size based on PowerTOST
- Sample size calculation for CEP study
- Lower bound for power of two combined TOST?
- Need of cross validation between 2 different cc range
- Reference trademark issue
- Visualization of power-law model
- Bear v2.8.3-1: critical update
- Manipulations with PK data in BE analysis
News
EMA 2018-07-05 Product-specific guidances
► read more…
ICH 2018-06-27 Draft Guideline on BCS-based biowaivers
► read more…
FDA 2018-05-21 Guidance on Bioanalytical Method Validation
► read more…
ICH 2016-10-07 Concept Papers on BCS- based biowaivers and bioanalytical method validation
► read more…
EMA 2015-11-19 Q & A document
► read more…
Guidance
FDA 2017-10-24 Drug-drug Interactions
► read more…
FDA 2016-12-21 ANDA Submissions ― Refuse-to-Receive Standards
► read more…
HPFB 2016-04-18 BE Standards for HVDPs
► read more…
EMA 2014-11-20 Guideline on MR dosage forms
► read more…
EMA 2014-10-23 Guideline on similar biological medicinal products
► read more…
FDA 2014-05-14 Draft Guidance:Clinical Pharmacology Data to Support a Demonstration of Biosimilarity to a Reference Product
► read more…
FDA 2014-03-18 Draft Guidance:BA and BE Studies Submitted in NDAs or INDs
► read more…
FDA 2013-12-09 Draft Guidance on Size, Shape, and Other Physical Attributes of Generic Tablets and Capsules
► read more…
FDA 2013-12-04 Draft Guidance on BE Studies with PK Endpoints for Drugs Submitted Under an ANDA
► read more…
Consultancy Services for Bioequivalence and Bioavailability Studies
BEBAC specializes in providing biostatistical services, contractor selection and supervision. We have wide experience with biostatistics, pharmacokinetics, and bioanalytics.
Our professional expertise covers advisory activities, planning and analysis of Phase I clinical trials.
We are able to support you in designing and evaluating studies, responding deficiency letters, as well as in the preparation for regulatory hearings, assessment and evaluation of CROs.
Helmut Schütz studied Chemical Engineering in Vienna and is an independent consultant in the domain of bioavailability and bioequivalence studies.
Mr Schütz has worked in the pharmaceutical industry and in an independent CRO, where he established a GALP-certified LIMS and held senior management positions, most recently as the head of a biostatistical department.
He has extensive experience with bioanalytics, pharmacokinetics, and biostatistics. His professional experience covers 38 years and more than 600 BA/BE studies.
Helmut Schütz is a member of the International Pharmaceutical Federation (FIP), the European Federation for Pharmaceutical Sciences (EUFEPS), the American Association of Pharmaceutical Scientists (AAPS), the International Biometric Society (IBS), the Austrian Pharmaceutical Association (ÖPhG), the European Network for Business and Industrial Statistics (ENBIS), and the Austrian Association of Consulting Engineers (FI).
Short CVout of office dates
| August | September | October | November | ||||||||||||||||
| M | T | W | T | F | M | T | W | T | F | M | T | W | T | F | M | T | W | T | F |
| 1 | 2 | 3 | 3 | 4 | 5 | 6 | 7 | 1 | 2 | 3 | 4 | 5 | 1 | 2 | 3 | ||||
| 6 | 7 | 8 | 9 | 10 | 10 | 11 | 12 | 13 | 14 | 8 | 9 | 10 | 11 | 12 | 6 | 7 | 8 | 9 | 10 |
| 13 | 14 | 15 | 16 | 17 | 17 | 18 | 19 | 20 | 21 | 15 | 16 | 17 | 18 | 19 | 13 | 14 | 15 | 16 | 17 |
| 20 | 21 | 22 | 23 | 24 | 24 | 25 | 26 | 27 | 28 | 22 | 23 | 24 | 25 | 26 | 20 | 21 | 22 | 23 | 24 |
| 27 | 28 | 29 | 30 | 31 | 29 | 30 | 31 | 27 | 28 | 29 | 30 | ||||||||
next presentations
24 September (Amman), 7–9 November (Athens).
BEBAC – Consultancy Services for
Bioequivalence and Bioavailability Studies
Ing. Helmut Schütz
Neubaugasse 36/1/11
1070 Vienna, Austria
T +43 (0)1 2311746
M +43 (0)699 10792458
E office@bebac.at
W https://bebac.at/
F https://forum.bebac.at/
Document date 2011-05-13 (last update 2018-08-16)
Accessed on Thursday, 16 August 2018 19:46 CEST (Europe/Vienna; UTC +02:00)
Site opened 2004-07-26 | document date 2011-05-13 | last update 2018-08-16